Now Playing
Opinion|Videos|June 12, 2024
Identifying Potential Candidates for CAR T-Cell Therapy
A panel of experts on multiple myeloma introduce themselves and discuss the initial process of identifying patients who are potential candidates for CAR T-cell therapy.
Advertisement
Episodes in this series
- Could you describe the initial process of identifying and referring potential candidates for CAR T-cell therapy from the community setting to an academic center?
- What patient specific factors might you consider?
- Are there any criteria that patients need to meet in order to be ready to move to a community setting?Does this vary between community settings?
- What are some challenges you are seeing when transitioning from community to academic settings?
Advertisement
Related to this article
Ralph V. Boccia, MD, FACP, noted how designated hospitals and a 24/7 on-call team support emergencies during bispecific step-up dosing.
Ralph V. Boccia, MD, FACP, explained the caregiver’s role in monitoring and reporting during bispecific antibody step-up dosing.
Ralph V. Boccia, MD, FACP, explained who needs REMS certification and which care team members need training to deliver bispecific antibodies.
Saad Z. Usmani, MD, MBA, FACP, FASCO, discussed quadruplet induction, extended maintenance, and when a community clinician should call a myeloma center.
Saad Z. Usmani, MD, MBA, FACP, FASCO, discussed the threshold he will act on in standard-risk disease, and the trial that would make the decision firmer.
In a retrospective analysis, teclistamab produced response rates numerically higher than in MajesTEC-1, with missed doses not compromising outcomes.
Data from the phase 3 OCEAN trial and others support the expanded approval for melflufen in patients with previously treated multiple myeloma.
In a phase 2 trial, CD38-targeted immune-PET detected active multiple myeloma in some patients with no signs of disease on standard fluorodeoxyglucose PET/CT.
Advertisement
Advertisement
Trending on CancerNetwork
1
FDA Approves Perioperative Durvalumab/Enfortumab Vedotin in MIBC
2
ACS Updates Prostate Cancer Screening Guideline With Risk-Based PSA Intervals
3
Why Caregivers Are Critical During Bispecific Step-Up Dosing
4
Prizlon-cel Earns FDA RMAT and Fast Track Designations in Relapsed LBCL
5